Lu S - Search Results

1

Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial.

Lu S, Pan H, Wu L, Yao Y, He J, Wang Y, Wang X, Fang Y, Zhou Z, Wang X, Cai X, Yu Y, Ma Z, Min X, Yang Z, Cao L, Yang H, Shu Y, Zhuang W, Cang S, Fang J, Li K, Yu Z, Cui J, Zhang Y, Li M, Wen X, Zhang J, Li W, Shi J, Xu X, Zhong D, Wang T, Zhu J. Lu S, et al. Signal Transduct Target Ther. 2023 Jun 30;8(1):249. doi: 10.1038/s41392-023-01454-z. Signal Transduct Target Ther. 2023. PMID: 37385995 Free PMC article. Clinical Trial.

2

Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.

Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ. Lu S, et al. Oncol Rep. 2008 Sep;20(3):581-7. Oncol Rep. 2008. PMID: 18695909

3

Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.

Zhang L, Hou X, Lu S, Rao H, Hou J, Luo R, Huang H, Zhao H, Jian H, Chen Z, Liao M, Wang X. Zhang L, et al. Among authors: lu s. Lung Cancer. 2010 Jan;67(1):114-9. doi: 10.1016/j.lungcan.2009.03.017. Lung Cancer. 2010. PMID: 19376608

4

Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.

Li Z, Yu Y, Lu J, Luo Q, Wu C, Liao M, Zheng Y, Ai X, Gu L, Lu S. Li Z, et al. Among authors: lu j, lu s. J Thorac Oncol. 2009 Jun;4(6):702-9. doi: 10.1097/JTO.0b013e3181a5269d. J Thorac Oncol. 2009. PMID: 19404215 Free article.

5

[Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].

Zhang YF, Yu YF, Lu S. Zhang YF, et al. Among authors: lu s. Zhonghua Yi Xue Za Zhi. 2009 Jun 9;89(22):1544-8. Zhonghua Yi Xue Za Zhi. 2009. PMID: 19953882 Chinese.

6

Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.

Zhang YF, Chen ZW, Lu S. Zhang YF, et al. Among authors: lu s. Chin Med J (Engl). 2009 Oct 20;122(20):2472-6. Chin Med J (Engl). 2009. PMID: 20079162

7

Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population.

Niu X, Chen Z, Shen S, Liu Y, Zhou D, Zhang J, Li Z, Yu Y, Liao M, Lu S, He L. Niu X, et al. Among authors: lu s. J Thorac Oncol. 2010 May;5(5):658-66. doi: 10.1097/JTO.0b013e3181d5e447. J Thorac Oncol. 2010. PMID: 20234319 Free article.

8

A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.

Yu YF, Chen ZW, Zhou Z, Song ZB, Li ZM, Jian H, Zhang YF, Lu S. Yu YF, et al. Among authors: lu s. Chemotherapy. 2010;56(6):472-7. doi: 10.1159/000321016. Epub 2010 Nov 23. Chemotherapy. 2010. PMID: 21099219

9

Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients.

Song Z, Yu Y, Chen Z, Lu S. Song Z, et al. Among authors: lu s. Med Oncol. 2011 Dec;28 Suppl 1:S605-12. doi: 10.1007/s12032-010-9753-3. Epub 2010 Nov 30. Med Oncol. 2011. PMID: 21116876

10

[Short-term intermittent prophylactic administration of recombinant human thrombopoietin attenuates chemotherapy-induced thrombocytopenia in lung cancer patients].

Xu YH, Cheng BJ, Lu S, Jian H, Zhou Z, Chen ZW, Ye XY. Xu YH, et al. Among authors: lu s. Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):395-9. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21875475 Clinical Trial. Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,071 results

Search Page

Filters